Logo

NMTC

NeuroOne Medical Technologies Corporation

NMTC

NeuroOne Medical Technologies Corporation • NASDAQ
$0.69 ▼ -0.71% (-0.01)
Market Cap $34.70 M
52w High $1.39
52w Low $0.40
Dividend Yield 0%
P/E -4.34
Volume 66.48K
Outstanding Shares 49.94M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $1.696M ▲ $2.801M ▼ $-1.501M ▲ -88.492% ▲ $-0.031 ▲ $-1.425M ▲
Q2-2025 $1.387M ▼ $3.451M ▲ $-2.271M ▼ -163.759% ▼ $-0.073 ▼ $-2.205M ▼
Q1-2025 $3.274M ▲ $215.682K ▼ $1.785M ▲ 54.528% ▲ $0.058 ▼ $2.175M ▲
Q4-2024 $272.284K ▼ $2.958M ▼ $-3.351M ▼ -1.231K% ▼ $0.34 ▲ $-2.955M ▼
Q3-2024 $825.776K $3.076M $-2.768M -335.142% $-0.1 $-2.731M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $8.04M ▲ $10.819M ▲ $2.642M ▼ $8.177M ▲
Q2-2025 $1.32M ▲ $4.457M ▼ $3.331M ▼ $1.126M ▼
Q1-2025 $1.134M ▼ $6.494M ▲ $3.559M ▼ $2.935M ▲
Q4-2024 $1.46M ▼ $5.37M ▲ $4.548M ▲ $822.013K ▼
Q3-2024 $1.62M $4.913M $1.901M $3.012M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-1.501M ▲ $-1.464M ▼ $-43.548K ▼ $8.226M ▲ $6.719M ▲ $-1.507M ▼
Q2-2025 $-2.271M ▼ $-56.144K ▼ $-3.171K ▲ $245.216K ▲ $185.901K ▲ $-59.315K ▼
Q1-2025 $1.785M ▲ $208.049K ▲ $-24.416K ▲ $-509.325K ▼ $-325.692K ▼ $183.633K ▲
Q4-2024 $-3.351M ▼ $-2.667M ▼ $-36.905K ▼ $2.544M ▲ $-159.935K ▲ $-2.704M ▼
Q3-2024 $-2.768M $-2.36M $-14.801K $1.561M $-814.678K $-2.375M

Five-Year Company Overview

Income Statement

Income Statement NeuroOne is still essentially a pre‑revenue company in the historical data shown, with no meaningful sales and recurring operating losses. Earnings per share have been negative every year, though losses per share appear to be gradually narrowing. The narrative suggests product revenue is beginning to ramp through its distribution partner, but the financial history still looks like an early-stage R&D-focused business rather than a mature commercial operation. Overall, the income statement reflects a classic development-stage med‑tech profile: high expenses relative to negligible revenue and ongoing net losses.

Balance Sheet

Balance Sheet The balance sheet is very small and thinly capitalized, with limited assets and cash, and no reported debt. Equity has been drifting down, which is typical when losses accumulate and must be covered by new capital infusions or dilution. The absence of debt reduces financial leverage risk, but also highlights that the company primarily depends on equity markets and partnerships to fund its activities. In short, the balance sheet offers little cushion and emphasizes execution and financing risk.

Cash Flow

Cash Flow Cash flow is consistently negative from operations, reflecting spending on people, research, and overhead without offsetting revenue. There is essentially no meaningful investment in physical assets, which fits a lean, technology‑heavy model but also means no hard assets backing the business. Free cash flow is negative year after year, indicating continued cash burn and reliance on external funding. The company’s ability to manage its burn rate and secure ongoing financing will be critical until commercial sales can meaningfully cover costs.

Competitive Edge

Competitive Edge Competitively, NeuroOne is trying to carve out a differentiated position with its thin‑film electrode platform, which promises less invasive procedures, clearer brain signals, and potentially lower immune response than older technologies. FDA clearances for its cortical, sEEG, and OneRF ablation system give it regulatory validation and a first‑mover edge in combining diagnosis and treatment with a single device. The exclusive distribution partnership with Zimmer Biomet gives it instant access to a large sales network, which is a major advantage for a small company. However, it still competes against larger, well‑funded device makers with broad product portfolios, and it is highly dependent on the success of its partnership and its ability to convert clinical interest into sustained adoption.

Innovation and R&D

Innovation and R&D Innovation is the core of NeuroOne’s story. Its patented thin‑film technology underpins a platform that can be used for recording, monitoring, stimulation, ablation, and potentially drug delivery in the brain and nervous system. The pipeline spans several sizable indications: trigeminal nerve ablation for severe facial pain, spinal cord stimulation for chronic back pain, deep brain stimulation for movement disorders, and long‑term drug delivery concepts. This breadth offers multiple shots on goal, but most of these programs are still in development and carry significant regulatory, clinical, and commercial execution risk. Success will depend on converting strong engineering ideas and early data into widely adopted clinical tools.

Summary

NeuroOne combines a very early‑stage financial profile with an ambitious neuromodulation technology platform. The historical numbers show a pre‑revenue, loss‑making company with a thin balance sheet and ongoing cash burn, typical of small med‑tech innovators. On the other hand, it has secured important FDA clearances, built a strategic relationship with a major industry player, and assembled a pipeline that targets several large neurological markets. The main opportunities lie in scaling commercial adoption of its approved products and advancing its pipeline, while the main risks center on funding needs, execution against larger competitors, and the uncertainties of clinical and regulatory outcomes. Overall, this is a high‑risk, high‑potential profile that depends heavily on successful commercialization of its technology platform over the coming years.

NEWS

September 8, 2025 · 4:05 PM UTC

NeuroOne® to Participate in Sidoti Small-Cap Conference on September 17th and 18th, 2025

Read more